Massive exercising of stock acquisition rights occurred up to November 6. Number of shares to be delivered: 5,600,000 shares; number of stock acquisition rights exercised: 56,000; proportion of total issued: 11.7%. Unexercised rights decreased from 328,460 to 272,460. This qualifies as exercising exceeding 10%.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4582","jir_company_name":"SymBio Pharmaceuticals Limited","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-11-09","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/11\/4582-20261109-01.pdf","jir_short_summary":"Massive exercising of stock acquisition rights occurred up to November 6. Number of shares to be delivered: 5,600,000 shares; number of stock acquisition rights exercised: 56,000; proportion of total issued: 11.7%. Unexercised rights decreased from 328,460 to 272,460. This qualifies as exercising exceeding 10%.","jir_summary":"### Status and Scale of Massive Exercising\nThis announcement reports on the massive exercising of the 70th stock acquisition rights. The number of shares to be delivered is 5,600,000 shares. The exercise price is undisclosed. The number of stock acquisition rights exercised is 56,000, representing 11.7% of the total issued. The number of issued shares at the end of the previous month for the target month was 87,378,960 shares, of which treasury shares are 91,394. Unexercised rights decreased from 328,460 to 272,460.\n\n### Impact and Future Developments\nBecause the massive exercising exceeds a certain proportion of listed shares, treatment for exercises exceeding regulatory limits may apply, making appropriate disclosure and monitoring of future trends important. Cases are suggested where restriction clauses under previously concluded purchase agreements may be excluded, so attention should be paid to dilution effects and the linkage with capital policy. It is necessary to confirm whether additional disclosures will be made going forward and to verify the status of treasury share holdings and the financial impact.","jir_financial_highlights":"Number of shares to be delivered: 5,600,000 shares\nNumber of stock acquisition rights exercised: 56,000\nProportion of total issued: 11.7%\nNumber of unexercised stock acquisition rights: 272,460 (Previously disclosed 328,460 \u2192 272,460 (decrease))\nNumber of issued shares (as of November 6): 87,378,960 shares (Includes 91,394 treasury shares)","jir_category":"","jir_hashtags":"#SymBioPharmaceuticals, #StockAcquisitionRights, #CapitalPolicy, #TreasuryStockRelated","jir_key_figures":"Number of shares to be delivered: 5,600,000 shares\nNumber of unexercised stock acquisition rights: 272,460\nTotal issued stock acquisition rights: 480,000 \u2192 11.7% exercised","jir_meta_title":"SymBio Pharmaceuticals Limited \u2014 Notice of Massive Exercising of Stock Acquisition Rights | November 2026","jir_meta_description":"SymBio Pharmaceuticals Limited announced massive exercising of the 70th stock acquisition rights. Number of shares to be delivered: 5,600,000 shares; unexercised rights reduced to 272,460. Exercise ratio to total issued: 11.7%. Monitor impacts on capital policy.","jir_og_title":"SymBio Pharmaceuticals Limited \u2014 Notice of Massive Exercising of Stock Acquisition Rights | November 2026","jir_og_description":"Massive exercising of stock acquisition rights occurred. Number of shares to be delivered: 5,600,000 shares; unexercised rights reduced to 272,460. Attention on effects to capital policy and future developments.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":60013,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"share_buyback","footnotes":""},"sector":[],"importance":[],"class_list":["post-145544","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n